

Publicaciones de Bergua Burgués, Juan Miguel (294 Resultados)

Artículos

Aspas Requena G, Montesinos P, Bérard E, Bertoli S..., **Bergua Burgues JM**. Intensive Chemotherapy With or Without Midostaurin in Adults ? 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study. Am J Hematol. 2026;

Aspas Requena G, Rodríguez-Veiga R, Gil C, Botella C, Aguiar E..., **Bergua Burgues JM**, et al. Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study. Am J Hematol. 2026;

Barragán E, Gil JV, Ayala R, Chillón C..., **Bergua J**. Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study . Blood Neoplasia. 2026;

Colmenares R, Barragán E, Rodríguez-Veiga R, Torres-Miñana L..., **Bergua J**. Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group. Bone Marrow Transplant. 2026;

Coucelo M, Sargas C, Ayala R, Larráyoiz MJ, Chillón MC, **Bergua J**, et al. Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories. Leuk Res. 2026;

Gil JV, Sargas C, Ayala R, Gutierrez NC..., **Bergua Burgues JM**. Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study . Blood. 2026;

Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, **Bergua JM**, et al. Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients . Am J Hematol. 2026; 101 (1): 89-96.

Montesinos P, Rodríguez-Veiga R, **Bergua JM**, Algarra Algarra JL, Botella C..., Casas Avilés I, et al. Quizartinib for Newly Diagnosed FLT3-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study. J Clin Oncol. 2026; 44 (1): 42-53.

Prados de la Torre E, Serrano J, Barragán E, Ayala R..., **Bergua Burgues JM**. CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry . Hematol Oncol. 2026; 44 (1): e70162.

Ribera JM, Torrent A, Morgades M..., **Bergua Burgues JM**. Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia . Blood. 2026;

Vitolo U, **Burgues JMB**, Duell J, Kwiatek M, Belada D, Jurczak W, et al. Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial . Lancet Haematol. 2026;

Alfonso-Pierola A, Martínez-Cuadrón D, Rodríguez-Veiga R, Gil C, Martínez-Sánchez P..., **Bergua JM**, et al. Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

. Leukemia. 2025; 39 (11): 2686-2696.

Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, **Bergua JM**, et al. Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma . Future Oncol. 2025; 21 (16): 1965-1983.

Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, **Bergua JM**, et al. Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2025; 43 (9): 1061-1072.

Boluda B, Rodríguez Viga R, Sargas C, Ayala R..., **Bergua J**. Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study. Cancers. 2025; 17 (5): 854.

Colmenares R, Álvarez N, Barragán E, Boluda B, Larrayoz MJ..., **Bergua J**, et al. Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry. Haematologica. 2025; 110 (7): 1623-1627.

DeZern AE, Thepot S, De Botton S, Patriarca A, Deeren D..., **Bergua Burgues JM**, et al. Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS . Blood Adv. 2025; 9 (16): 4090-4099.

Lloret-Madrid P, Boluda B, Martínez-López J, **Bergua J**, Rodriguez Arbolí E, Labrador J, et al. Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study. Cancer. 2025; 131 (1): e35696.

Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW..., **Bergua Burgués JM**, et al. [Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma](#). *J Clin Oncol*. 2025; 43 (35): 3698-3705.

Rodríguez-Arbolí E, Rodríguez-Veiga R, Soria-Saldise E, **Bergua JM**, Caballero-Velázquez T, Arnán M, et al. [A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX](#). *Cancer*. 2025; 131 (1): e35618.

Rodríguez-Veiga R, Gil C, Sobas M, Torres-Miñana L..., **Bergua J**. [A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study](#). *Haematologica*. 2025;

Serrano J, Martínez-Cuadrón D, Gil C, Bernal T, Tormo M..., **Bergua J**, et al. [Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience](#). *Transplant Cell Ther*. 2025; 31 (5): 299.e1-299.e14.

Solana-Altabella A, Navarro-Vicente I, Rodríguez-Arbolí E, Noriega V, Serrano J..., **Bergua-Burgues JM**, et al. [Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study](#). *Cancers*. 2025; 17 (17): 2844.

Valhondo I, Pera A, Hassouneh F..., **Bergua JM**, Arcos MJ, Casas-Avilés I, et al. [Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival](#). *Cancer Immunol Immunother*. 2025; 74 (11): 325.

Westin J, Tycel JP, Amitkumar M..., **Bergua Burgués JM**. [Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study](#) . Blood Adv. 2025; 9 (10): 2461-2472.

Alegre A, Gironella M, Escalante F, **Bergua JM**, Martínez-Chamorro C, López A, et al. [Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting](#) . Hemasphere. 2024; 8 (7): e81. F.I.: 14.6

De la Torre EP, Serrano J, Martínez-Cuadrón D, Torres L, Sargas C..., **Bergua JM**, et al. [Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry](#) . Haematologica. 2024; 109 (8): 2682-2687.

Labrador J, Martínez-Cuadrón D, Boluda B, Serrano J, Gil C..., **Bergua JM**, et al. [Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry](#) . Cancer. 2024; 130 (20): 3436-3451. F.I.: 5.1

Martin-Sánchez E, Blanco Fernández L, Kim PS, Bisht K, Wang H..., **Bergua Burgués JM**, et al. [Targeting CD38 by isatuximab and a CD38/CD3xCD28 trisppecific T-cell engager in old patients with acute myeloid leukemia](#) . Blood Adv. 2024; 8 (15): 3875-3879.

Martínez-Cuadrón D, Megías-Vericat JE, Gil C, Bernal T, Tormo M..., **Bergua J**, et al. [Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry](#) . Haematologica. 2024; 109 (1): 115-128.

Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B..., **Bergua JM**, et al. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial. *Haematologica*. 2024; 109 (2): 543-552.

Suárez EU, Boluda B, Lavilla E, Tormo M, Botella C..., **Bergua-Burgués JM**, et al. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens? . *Ann Hematol*. 2024; 103 (8): 2845-2851. F.I.: 2.4

Belada D, Kopeckova K, **Bergua Burgués JM**, Stevens D, André M, Pérez Persona E, et al. Safety and efficacy of tafasitamab ± lenalidomide added to first-line R²CHOP for DLBCL: Phase 1b First-MIND study . *Blood*. 2023; 142 (16): 1348-1358. F.I.: 21

Bernal T, Fernández Moreno A, Lalglesia A de, Benavente C..., **Bergua Burgués JM**. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry. *Cancer Med*. 2023; (14): 14892-14901. F.I.: 2.9

González Barca E, Tomás-Roca L, Esteve A, Rodríguez M, Gato L..., **Bergua Burgués JM**, et al. Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets. *Am J Hematol*. 2023; 98 (6): E134-E138. F.I.: -

Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C..., **Burgues JMB**, et al. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4. *Haematologica*. 2023; 108 (1): 34-31. F.I.: 8.2

Martín García-Sancho A, Baile M, Dlouhy I, Sancho JM..., **Bergua J**. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO

. Br J Haematol. 2023; 203 (2): 202-211. F.I.: 5.1

Moreno AF, Lavín-Alconero L, de Ugarriza PL, Blanco LS, Hernández SC, **Burgués JMB**, et al. FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety. Trials. 2023; 24 (1): 694. F.I.: 2

Sargas C, Ayala R, Larráyoiz MJ, Chillón MC, Rodríguez-Arboli E..., **Bergua J**, et al. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J. 2023; 13 (1): 77. F.I.: 12.9

Sargas C, Ayala R, Larráyoiz MJ, Chillón MC..., **Bergua JM**. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry. Cancers. 2023; 15 (2): 438. F.I.: 4.5

Simoës C, Chillon MC, Martínez-Cuadrón D, Calasanz MJ..., **Bergua Burgués JM**. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia. Blood Adv. 2023; 7 (1): 167-173. F.I.: 7.4

Simoës C, Villar S, Ariceta B, Garcés JJ, Burgos L..., **Bergua JM**, et al. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia. Br J Haematol. 2023; 201 (6): 1239-1244. F.I.: -

Sobas M, Knopinska-Posluszny W, Piłkowska-Jakubas B..., **Bergua Burgués JM**. Incidence, risk factors and outcomes of second neoplasm in patients with acute promyelocytic leukemia: the PETHEMA -PALG experience. Ann Hematol. 2023; F.I.: 3

Ayala R, Carreño-Tarragona G, Barragán E, Boluda B, Larráyoiz MJ..., **Bergua J**, et al. Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

. Cancers. 2022; 14 (23): 5799. F.I.: 5.2

Bérard E, Röllig C, Bertoli S, Pigneux A, Tavitian S..., **Bergua J**, et al. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. Blood Cancer J. 2022; 12 (7): 107. F.I.: 12.8

Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J..., **Bergua JM**, et al. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. Cancers. 2022; 14 (9): 2342. F.I.: 5.2

Martínez López J, Montesinos P, López Muñoz N, Ayala R, Martínez Sánchez P..., **Bergua Burgues JM**, et al. Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia. Med Int. 2022; 2 F.I.: -

Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, Martínez-Sánchez P, Rodríguez-Arbolí E..., **Bergua Burgués JM**, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022; 6 (4): 1278-1295.

Martínez-Cuadrón D, Serrano J, Mariz J, Gil C, Tormo M..., **Bergua J**, et al. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. Cancers. 2022; 14 (11): 2817. F.I.: 5.2

Ribera JM, García O, Buendía-Ureña B, Terol MJ, Vicent A..., **Bergua J**, et al. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. Leuk Lymphoma. 2022; 63 (8): 1993-1996. F.I.: -

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M..., **Bergua-Burgués JM**, et al. **Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma**. *N Engl J Med*. 2022; 386 (4): 351-363. F.I.: 158.5

Villar S, Ariceta B, Agirre X, Urribarri AD, Ayala R..., **Bergua JM**, et al. **The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients**. *Front Oncol*. 2022; (12): 1054458. F.I.: 4.7

Ayala R, Rapado I, Onecha E, Martínez-Cuadrón D, Carreño-Tarragona G, **Bergua JM**, et al. **The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial**. *Cancers*. 2021; 13 (10): 2458.

Martínez Sánchez MP, Megías-Vericat JE, Rodríguez-Veiga R..., **Bergua JM**, Torrent A, **Suárez Varela S**, et al. **A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients**. *Ann Hematol*. 2021; 100 (6): 1497-1508.

Martínez-Cuadrón D, Serrano J, Gil C, Tormo M, Martínez-Sánchez P..., **Bergua J**, et al. **Evolving treatment patterns and outcomes in older patients (>60 years) with AML: changing everything to change nothing?**. *Leukemia*. 2021; 35 (6): 1571-1585.

Moriano B, Barragan E, **Ferré O**, Casas I, Prieto Fernández J, Hernández C, et al. **NPM1+ /FLT3- Acute Myeloid Leukemia after JAK2-V617F+ Essential Thrombocythemia. Management and Prognosis**. *Plasmatol*. 2021; 15 1-4.

Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q..., **Bergua JM**, et al. **ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma**

. J Clin Oncol. 2021;

Palanques-Pastor T, Megías-Vericat JE, Martínez P, López Lorenzo JL, Cornago Navascués J..., **Bergua Burgués JM**, et al. [Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group](#). *Leuk Lymphoma*. 2021; 62 (12): 2928-2938.

Récher C, Röllig C, Bérard E, Bertoli S, Dumas PY..., **Bergua J**, et al. [Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries](#). *Leukemia*. 2021;

Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J..., **Bergua Burgues JM**, et al. [Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia](#). *Blood*. 2021; 137 (14): 1879-1894.

Ribera JM, Morgades M, Coll R, Barba P, López-Lorenzo JL..., **Bergua J**, et al. [Frequency, clinical characteristics and outcome of adults with acutelymphoblastic leukemia and COVID 19 infection in the first vs.second pandemic wave in Spain](#). *Clin Lymphoma Myeloma Leuk*. 2021; 21 (10): e801-e809.

Sargas C, Ayala R, Chillón MC, Larráyoiz MJ, Carrillo-Cruz E..., **Bergua J**, et al. [Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project](#). *Haematologica*. 2021; 106 (12): 3079-3089. F.I.: 9.941

Simoës C, Paiva B, Martínez-Cuadrón D, **Bergua JM**, Vives S, Algarra L, et al. [Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial](#). *Blood Adv*. 2021; 5 (3): 760-770.

Vives S, Martínez-Cuadrón D, **Bergua Burgues J**, Algarra L, Tormo M, Martínez-Sánchez MP, et al. [A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia](#)

. Cancer. 2021;

Zeidner JF, Lin TL, Vigil CE, Fine G, Yair Levy M..., **Bergua Burgués JM**, et al. [A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia](#). Blood Cancer J. 2021; 11 (10): 175.

Montesinos P, **Bergua J**, Infante J, Esteve J, Guimaraes JE, Sierra J, et al. [Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus](#) . Ann Hematol. 2020; 99 (3): 675.

Ribera JM, García O, Chapchap EC, Gil C, González-Campos J..., **Bergua JM**, et al. [Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy](#) . Clin Lymphoma Myeloma Leuk. 2020; 20 (8): e513-e522. F.I.: 3.231

Ribera JM, Morgades M, Montesinos P, Tormo M..., **Bergua J**, PETHEMA Group Spanish Society of Hematology, et al. [A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLREo8 PETHEMA trial](#) . Cancer Med. 2020; 9 (7): 2317-2329. F.I.: 4

Rodríguez-Medina C, Martínez-Cuadrón D, Cano I, Gil C, Tormo M..., **Bergua-Burgues JM**, et al. [Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" \[Leuk. Res. 92 \(March\) \(2020\) 106352\]](#) . Leuk Res. 2020;

Rodríguez-Medina C, Martínez-Cuadrón D, Cano I, Gil C, Tormo M..., **Bergua-Burgues JM**, et al. [Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study](#). Leuk Res. 2020; 92 106352. F.I.: 3.156

Sitges M, Boluda B, Garrido A, Morgades M, Granada I ..., **Bergua J**, et al.

Acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). study of 61 patients treated with intensive protocols. Eur J Haematol. 2020; 105 (2): 138-147. F.I.: 2.997

Sobas M, Rodriguez-Veiga R, Vellenga E, Paluszewska M, De la Serna J..., **Bergua J**, et al. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. Eur J Haematol. 2020; 104 (3): 162-169. F.I.: 2.997

Valhondo I, Hassouneh F..., **Bergua JM**, Arcos MJ, Bañas H, Casas-Avilés I, et al. Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia. Cancers. 2020; 12 (8): 2171. F.I.: 6.639

Villaescusa T, Vázquez L, **Bergua JM**, García J, Romero A..., Grupo de Infecciones en pacientes hematológicos. Sociedad Andaluza de Hematología y Hemoterapia, et al. Micafungina como profilaxis antifúngica en pacientes hematológicos no trasplantados. Rev Esp Quimioter. 2020; 33 (1): 44-48. F.I.: 1.553

Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, et al. Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. Eur J Haematol. 2019; 102 (1): 79-86. F.I.: 2.220

Bogliolo M, Pujol R, Aza-Carmona M, Muñoz-Subirana N, Rodríguez-Santiago B, Casado JA, et al. Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. J Med Genet. 2019; F.I.: 4.943

Labrador J, Luño E, Vellenga E, Brunet S, González-Campos J, Chillón MC, et al. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

. Leuk Lymphoma. 2019; 60 (5): 1146-1155. F.I.: 2.969

Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G4, Pérez-Oteyza J, García-Boyerero R, et al. [A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients](#) . Leuk Res. 2019; 76 1-10. F.I.: 2.214

Megías-Vericat JE, Martínez-Cuadrón D, López JM, **Bergua JM**, Tormo M, Serrano J, et al. [Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia](#) . Mediterr J Hematol Infect Dis. 2019; 11 (1): e2019016. F.I.: 1.600

Montesinos P, **Bergua J**, Infante J, Esteve J, Guimaraes JE, Sierra J, et al. [Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus](#) . Ann Hematol. 2019; 98 (11): 2467-2483. F.I.: 2.904

Sánchez-Correa B, Valhondo I, Hassouneh F, López-Sejas N, Pera A, **Bergua JM**, et al. [DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy](#) . Cancers. 2019; 11 (6): 877. F.I.: 6.126

Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, et al. [An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens](#) . Leuk Lymphoma. 2019; 60 (4): 1030-1035. F.I.: 2.969

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. [Performance of the Medical Research Council \(MRC\) and the Leukemia Research Foundation \(LRF\) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia](#) . Leuk Lymphoma. 2019; 60 (1): 246-249. F.I.: 2.969

Martínez-Cuadrón D, Boluda B, Martínez P, **Bergua J**, Rodríguez-Veiga R, Esteve J, et al. [Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF \(PLERIFLAG regimen\) for the treatment of patients with the first early-relapsed or refractory acute myeloid](#)

leukemia. *Ann Hematol.* 2018; 97 (5): 923.

Martínez-Cuadrón D, Boluda B, Martínez P, **Bergua J**, Rodríguez-Veiga R, Esteve J, et al. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. *Ann Hematol.* 2018; 97 (5): 763-772. F.I.: 2.850

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, et al. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. *Leuk Lymphoma.* 2018; 59 (1): 146-154. F.I.: 2.674

Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, et al. Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. *Leuk Res.* 2018; 68 79-84. F.I.: 2.066

Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, et al. Efficacy and safety of native versus pegylated *Escherichia coli* asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. *Leuk Lymphoma.* 2018; 59 (7): 1634-1643. F.I.: 2.674

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. *Blood Adv.* 2018; 2 (8): 923-932.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. *Biol Blood Marrow Transplant.* 2018; 24 (8): 1754-1758. F.I.: 3.599

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, et al. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. *Leuk Lymphoma*. 2017; 58 (1): 145-152. F.I.: 2.644

Sánchez-Correa B, Bergua JM, Pera A, Campos C, Arcos MJ, Bañas H, et al. In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients. *Front Immunol*. 2017; 8 931. F.I.: 5.511

Tarazona R, Sánchez-Correa B, Casas-Avilés I, Campos C, Pera A, Morgado S, et al. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy. *Cancer Immunol Immunother*. 2017; 66 (2): 233-245. F.I.: 4.225

Sánchez-Correa B, Campos C, Pera A, Bergua JM, Arcos MJ, Bañas H, et al. Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies? . *Cancer Immunol Immunother*. 2016; 65 (4): 453-463.

Purroy N, Bergua J, Gallur L, Prieto J, López LA, Sancho JM, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. *Br J Haematol*. 2015; 169 (2): 188-198.

Knapper S, Chevassut T, Duarte R, Bergua JM, Salamero O, Johansen M, et al. Elacytarabine in relapsed/refractory acute myeloid leukaemia: An evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. *Leuk Res*. 2014; 38 (3): 346-351.

Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final

results of the PETHEMA . J Clin Oncol. 2014; 32 (15): 1595-1604.

Ribera JM, García O, Grande C, Esteve J, Oriol A, **Bergua J**, et al. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013; 119 (9): 1660-1668.

Sánchez-Correa B, **Bergua JM**, Campos C, Gayoso I, Arcos MJ, Bañas H, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013; 61 (3): 885-891.

Purroy N, **Bergua J**, Gallur L, Prieto J, Sancho JM, López L, et al. Dose-adjusted EPOCH plus Rituximab in untreated patients with poor prognosis large B-cell, with analysis of germinal center and activated B-cell biomarkers. A phase IV study conducted by the Spanish PETHEMA Group . Blood. 2011; 118 (21(ASH Annual Meeting Abstracts) Abstract 593): 1-1.

Montesinos P, González JD, González J, Rayón C, de Lisa E, Amigo ML, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. J Clin Oncol. 2010; 28 (24): 3872-3879.

Bergua JM, Cabrera C, Bañas H.. Hepatitis B Virus Infection. N Engl J Med. 2009; 360 (3): 304-304.

Capote F.J, González Barca E, Oriol A, Romero Aguilar A, Leon A, Fernández Calvo F.J, et al. Hiper CVAD followed by Rituximab purging previous to autologous stem-cell transplantation as therapy of Mantle cell lymphoma. Results of Manto 2000 study.. Blood. 2009; 114 (22):

Molina Infante J, **Bergua Burgués J**, Fernández González N. Diarrhoea caused by colonic relapse of follicular lymphoma. Br J Haematol. 2009; 146 (5):

Ripollés L, Ortega M, Ortuño F, , Losada J, Ojanguren J, et al. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. *Cancer Genet Cytogenet.* 2006; 171 (1): 57-64.

Mollejo M, Lloret E, Solares J, Bergua JM, Mateo M, Piris MA, et al. Splenic involvement by blastic mantle cell lymphoma (large cell/anaplastic variant) mimicking splenic marginal zone lymphoma . *Am J Hematol.* 1999; 62 (4): 242-246.

Artículos de revistas electrónica

Simoes C, González C, Vergez F..., Bergua JM. Data-driven flow cytometry classification of blast differentiation in elderly patients with acute myeloid leukemia . *Blood Neoplasia.* [Internet]. 2024; 1(3) [Consultado el 24 de junio de 2024]; A|10.1016/j.bneo.2024.100027 Citado en: PubMed; PMID 40453058

Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A..., Bergua J, et al. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols . *Hemasphere.* [Internet]. 23 de diciembre de 2022 [Consultado el 10 de enero de 2023]; 7 (1): e810. A|10.1097/HS9.0000000000000810 Citado en: PubMed; PMID 36583094

F.I.: 9.1

Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, Carrillo-Cruz E, Gil-Cortés C..., Bergua JM, et al. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study . *Transplant Cell Ther.* [Internet]. 8 de enero de 2021 [Consultado el 14 de abril de 2021]; 27 (4): 311.e1-311.e10. 10.1016/j.jtct.2020.12.029 Citado en: PubMed; PMID 33836871

Libros

Montesinos P, Barragán E, Lloret P..., Bergua J, [C. científico y redacción]. [Guía asistencial del Paciente Anciano-Paciente Unfit \(Guía PAPU-70+\)](#). PETHEMA; 2025.

Libros electrónicos

Bergua JM. [Recomendaciones para el diagnóstico y el tratamiento de la infección por el virus de la hepatitis C](#). [Internet]. Madrid: Real Fundación Victoria Eugenia y Federación Española de Hemofilia; 2008. [21 de febrero de 2019].

Trabajos presentados a Congresos

Domínguez Mora AR, Bermejo Vega N, Calzadilla Román KS, Casado Cabanillas V, Macías Maeso J, Román Molano LG, et al. [Desaparición espontánea de un inhibidor bajo tratamiento con Emicizumab en un paciente con Hemofilia A leve](#). En: XI Curso de Coagulopatías; 25-27 de febrero de 2026; Baeza: 2026.

Domínguez Mora AR, Calzadilla Román KS, Casado Cabanillas V, Macías Maesp J, Rodríguez Alamo YC, Román Molano LG, et al. [Debut de mastocitosis sistémica en relación a la colocación de DIU hormonal](#). En: Congreso Regional SCLHH/SOEXX; 13-14 de marzo de 2026; Plasencia: 2026.

Aguirre Lora A, Serrano López J..., Bergua J. [CPX-351 en leucemia aguda mieloblástica alto riesgo: análisis de pacientes de registro PETHEMA](#). En: LXVII Congreso Nacional de la SEHH. XLI Congreso Nacional de la SETH; 9-11 de octubre de 2025; Oviedo: 2025.

Aspas Requena G, Rodríguez Veiga R..., **Bergua Burgues JM**. Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salvage score: A pethema registry study . En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Ayala Díaz RM, **Bergua Burgues JM**, Martín Muñoz A. Papel de la evaluación de la EMR por NGS- Clonesight en el pronóstico de pacientes mayores con diagnóstico de leucemia mieloide aguda tratados con tripletes en el ensayo clínico VENAQUI. En: LXVII Congreso Nacional de la SEHH. XLI Congreso Nacional de la SETH; 9-11 de octubre de 2025; Oviedo: 2025.

Bergua Burgués JM, Bergua Alcaine P..., Carnicero González F, Cabrera Silva C, Cáceres S, Moriano Palacios B, et al. Resultados a largo plazo del trasplante autólogo de progenitores hematopoyéticos como terapia de rescate en pacientes con linfoma de Hodgkin refractario/resistente: supervivencia libre de enfermedad, segundas neoplasias y enfermedad coronaria . En: LXVII Congreso Nacional de la SEHH. XLI Congreso Nacional de la SETH; 9-11 de octubre de 2025; Oviedo: 2025.

Bertoli S, Landberg N..., **Bergua Burgues JM**. The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy. En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Bertoli S, Landberg N..., **Bergua Burgues JM**. The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy. En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Botafogo V, Morgades M..., **Bergua J**. Respuesta al tratamiento y supervivencia de los pacientes con leucemia aguda linfoblástica B con reordenamiento de KMT2A incluidos en el protocolo Pethema LAL-19 . En: LXVII Congreso Nacional de la SEHH. XLI Congreso Nacional de la SETH; 9-11 de octubre de 2025;

Oviedo: 2025.

Casado Cabanillas V, Calzadilla Román KS, Patiño Culma DC, Domínguez Mora AR, Román Molano L, Valderrama Rosa AM, et al. **Enfermedad de Erdheim-Cheste: una entidad poco común**. En: LXVII Congreso Nacional de la SEHH. XLI Congreso Nacional de la SETH; 9-11 de octubre de 2025; Oviedo: 2025.

Cicconi L, Othman J, Spagnoli A..., **Bergua Burgues JM**. **Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study**. En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Colmenares R, Barragán E, Rodríguez Veiga R..., **Bergua Burgues JM**. **Impact of molecular profile and variant allele frequency in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group**. En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

De la Fuente Burguera A, Diaz Beya M..., **Bergua Burgues JM**. **No todas las leucemias mieloides agudas con mutación FLT3 son de riesgo intermedio en la era de los inhibidores de FLT3**. En: LXVII Congreso Nacional de la SEHH. XLI Congreso Nacional de la SETH; 9-11 de octubre de 2025; Oviedo: 2025.

Jang JH, Barrentxea Lekue C, **Bergua Burgues JM**. **Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis**. En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Molica M, Miralles G, Dillon R..., **Bergua Burgues JM**. **Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients**. En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Montesinos P, Fuente Burguera A de la, García Avila S..., **Bergua Burgues JM**. Preliminary results from RIVER-81, a phase 2 study of romaciclub (RVU120) + venetoclax in patients with acute myeloid leukemia failing first-line venetoclax + hypomethylating agent (HMA). En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Mora Raya A, Colmenares R..., **Bergua Burgues JM**. Monitorización de la evolución clonal mediante NGS y su impacto pronóstico en LMA de novo tratada con tripletes en el ensayo VENEQUI. En: LXVII Congreso Nacional de la SEHH. XLI Congreso Nacional de la SETH; 9-11 de octubre de 2025; Oviedo: 2025.

Paiva B, Burgos L, González C..., **Bergua Burgues JM**. Measurable residual disease (MRD) assessment as an early end point of treatment efficacy in acute myeloid leukemia (AML): A pethema study of 2,623 patients (Pts) treated with intensive therapy. En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Ribera Santasusana J, Torrent Catarineu A, Morgades De La Fe M, Barrena Delfa S..., **Bergua Burgués J**. Combinación del riesgo genético basal y el aclaramiento de la enfermedad residual para asignar el tratamiento post-remisión en los pacientes adultos con leucemia aguda linfoblástica (LAL) sin cromosoma filadelfia (PH-). Resultados finales del protocolo P LAL19. En: LXVII Congreso Nacional de la SEHH. XLI Congreso Nacional de la SETH; 9-11 de octubre de 2025; Oviedo: 2025.

Sargas C, Boudry A, Lloret Madrid P..., **Bergua Burgues JM**. Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial. En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Solana-Altabella A, Moscardó A, Lloret Madrid P..., **Bergua Burgues JM**. Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial . En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Torrent A, Morgades M Barrera S..., **Bergua Burgues JM**. Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial . En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Torrent, Morgades M, Barrera S..., **Bergua Burgues JM**. Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial. En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Vassilakopoulos T, Muñoz J, Huang H..., **Bergua Burgues JM**. Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoDTM agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma . En: 67th ASH Annual Meeting; 6-9 de diciembre de 2025; 2025.

Navarro Vicente I, Solana Altabella A, Sobas M..., **Bergua Burgues J**. Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: A Pethema/PALG Study . En: 66th ASH Annual Meeting; 7-10 de diciembre de 2024; San Diego: 2024.

Patiño Culma DC, Ibáñez Espacio F, Casado Cabanillas V, Calzadilla Román KS, Domínguez Mora AR, Higuero Saavedra V, et al. Anticuerpos de baja prevalencia: anti-U. Descripción caso clínico de interés . En: Primeras Jornadas de Medicina Transfusional en Extremadura ; 4 de octubre de 2024; Cáceres: 2024.

Valderrama Rosa A, Bañas Llanos M, Bermejo Vega N, Calzadilla Román K, Casado Cabanillas V, Patiño Culma D, et al. [Citometría de flujo: una ventana diagnóstica al síndrome linfoproliferativo autoinmune. Estudio de un caso](#). En: LXVI Congreso Nacional SEHH XL Congreso Nacional SETH; 24-26 de octubre de 2024; Palma de Mallorca: 2024.

Valderrama Rosa A, Bañas Llanos M, Casas Avilés I, Román Molano L, Ibañez Espacio F, Cáceres Hernández S, et al. [Diagnóstico de neoplasias en fluidos corporales: el valor de la citometría de flujo](#). En: LXVI Congreso Nacional SEHH XL Congreso Nacional SETH; 24-26 de octubre de 2024; Palma de Mallorca: 2024.

Bergua Burgues JM, Tarazona R, García Casado J, Gordillo JJ, Casas Aviles I, Rodríguez Veiga R, et al. [A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial](#). En: 65th ASH Annual Meeting; 9-12 de diciembre de 2023; San Diego: 2023.

Bergua Burgués JM, Rodríguez-Veiga R, Cano Ferri I..., Montesinos P. [Update results of VEN-A-QUI study: a phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: Azacitidine or low-dose Cytarabine with Venetoclax and Quizartinib](#). En: 28 th Congress of the European Hematology Association; 8-15 de junio de 2023; Frankfurt: 2023.

Bilbao C, Stuckey R..., Bergua Burgues JM. [FLT3-ITP mutation characterization with classical PCR methodology versus capture and amplicon based NGS platforms: a PETHEMA NGS-AML project](#). En: 28 th Congress of the European Hematology Association; 8-15 de junio de 2023; Frankfurt: 2023.

Carlo-Stella C, Kwiatek M, Chung M, Móciková H, Bergua-Burgues JM, Gao S, et al. [LOTIS-5, an ongoing phase 3 randomized study of Loncastuximab Tesirine with Rituximab \(Lonca-r\) versus immunochemotherapy in patients with R/R DLBCL](#)

. En: 17th International Conference on Malignant Lymphoma; 13-17 de junio de 2023; Lugano, Switzerland: 2023. p. 850-851

Colmenares R, Sargas C..., **Bergua Burgues JM**. **AML-443 Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)** . En: Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting; 2023; 2023.

González C, Simoes, Ariceta B, Martínez-Cuadron D..., **Bergua Burgues JM**. **Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)**. En: 65th ASH Annual Meeting; 9-12 de diciembre de 2023; San Diego: 2023.

Koenig K, **Bergua Burgues JM**, Montesinos P..., Curran E. **Safety and efficacy of LP-108 as monotherapy and combined with azacitidine in patients with relapsed/refractory myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia**. En: 28 th Congress of the European Hematology Association; 8-15 de junio de 2023; Frankfurt: 2023.

Lancet J, Ravandi F, Monteseinos P..., **Bergua Burgues JM**. **Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study**. En: 65th ASH Annual Meeting; 9-12 de diciembre de 2023; San Diego: 2023.

Martínez-Cuadron D, Boluda B, Lorenzo Algarra J..., **Bergua Burgues JM**. **Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry**. En: 65th ASH Annual Meeting; 9-12 de diciembre de 2023; San Diego: 2023.

Montesinos P, Rodríguez-Veiga R, **Bergua Burgues JM**, Algarra L..., Labrador J. Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD wild- type AML . En: 28 th Congress of the European Hematology Association; 8-15 de junio de 2023; Frankfurt: 2023.

Mosquera Orgueira A, Pérez Encinas M, Díaz Arias JA..., **Bergua Burgues JM**. Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial . En: 65th ASH Annual Meeting; 9-12 de diciembre de 2023; San Diego: 2023.

Mosquera Orgueira A, Pérez Encinas M, Díaz Arias JA..., **Bergua Burgues JM**. The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial . En: 65th ASH Annual Meeting; 9-12 de diciembre de 2023; San Diego: 2023.

Navarro Vicente I, Lloret Madrid P, Solana Altabella A..., **Bergua Burgues JM**. Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study) . En: 65th ASH Annual Meeting Abstracts; 2023.

Navarro Vicente I, Lloret Madrid P. Solana-Altabella A..., **Bergua Burgues JM**. Clinical Features and Treatment in Patients Diagnosedwith Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema EpidemiologicRegistry (EPI-BLAS study) . En: 65th ASH Annual Meeting; 9-12 de diciembre de 2023; San Diego: 2023.

Olszewski AJ, Eradat H, Avigdor A, Horowitz NA..., **Bergua Burgues JM**. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

. En: 65th ASH Annual Meeting; 9-12 de diciembre de 2023; San Diego: 2023.

Ravandi F, Lancet J..., **Bergua Burgues JM**. **COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330)**. En: Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting; 2023; 2023.

Ribera JM, Morgades M, García Calduch O..., **Bergua Burgues JM**. **Feasibility and outcome after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia. Results of the BURKIMAB14 trial**. En: 28 th Congress of the European Hematology Association; 8-15 de junio de 2023; Frankfurt: 2023.

Rosenberg A, Baljevic M, Alegre Amor A..., **Bergua Burgues JM**. **COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)**. En: Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting; 2023; 2023.

Sobas M, Knopinska-Posluszny W, **Bergua Burgues JM**, Rodríguez-Veiga R, Cano Ferri I..., Montesinos P, et al. **Incidence, risk factors and outcomes od second neoplasm in patients with acute promyelocytic leukemia: the PETHEMA -PALG experience**. En: 28 th Congress of the European Hematology Association; 8-15 de junio de 2023; Frankfurt: 2023.

Torno M, Día Beya M, Fenández Moreno A..., **Bergua Burgues JM**. **Midostaurin plus 7+3 or Quizartinib plus 7+3 in FLT3-ITD mutated AML**. En: 28 th Congress of the European Hematology Association; 8-15 de junio de 2023; Frankfurt: 2023.

Barba P, Morgades M, Montesinos P, González Campos J..., **Bergua Burgues J**. **Impact of center characteristics and macroeconomic factors on the outcome of adult patients with acute lymphoblastic leukemia treated with peiatric-inspired protocols**. En: 27th Congress of the European Hematology; 9-17 de

junio de 2022; Vienna: 2022.

Belada D, Kopeckova K, **Bergua Burgués J**, Stevens D, Nowakowski G, Waldron-Lynch M, et al. **Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab ± Lenalidomide + R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma** . En: Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting; 25-27 de agosto de 2022; Los Angeles: 2022.

Belada D, Kopeckova K, **Bergua Burgues J**, Stevens D..., Dreyling M. **Pharmacokinetics and pharmacodynamics in first-mind: a phase IB, open-label, randomized study of tafasitamab+ + lenalidomide + R-Chop in patients with newly diagnosed diffuse large B-cell lymphoma** . En: 27th Congress of the European Hematology; 9-17 de junio de 2022; Vienna: 2022.

Bergua Burgues JM, Rodríguez Veiga R, Cano I..., **Casas Avilés I**. **Preliminary results of VEN-A-QUI Study: a phase 1-2 trial to assess the safety and efficacy of the combination of azacitidine or low- dose cytarabine with venetoclax and quizartinib in newly diagnosed** . En: 27th Congress of the European Hematology; 9-17 de junio de 2022; Vienna: 2022.

Bernal T, Rad G, Laiglesia A de, Benavente C..., **Bergua Burgues J**. **Real life experience using front-line CPX-351 for therapy-related and AML-MRC: results from the spanish Pethema registry** . En: 27th Congress of the European Hematology; 9-17 de junio de 2022; Vienna: 2022.

Boluda B, Sargas C, Ayala R..., **Bergua J**. **Conventional PCR Versus Next Generation Sequencing for Diagnosis of *FLT3*, *IDH* and *NPM1* Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group** . En: 64th ASH Annual Meeting; 2022.

De la Fuente A, Diaz Beya M, Beneit P..., **Bergua Burgues J**. **Midostaurin plus intensive chemotherapy in *FLT3* mutated AML** . En: 27th Congress of the European Hematology; 9-17 de junio de 2022; Vienna: 2022.

Flowers C, Tilly H, Morschhauser F, Sehn LH, Friedberg JW..., **Bergua-Burgués JM**, et al. Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) therapy in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL): results from the phase III Polarix study. En: Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022); 28 de septiembre a 3 de octubre de 2022; Houston: 2022. p. S358-S359

Fuente A de la, Díaz Beya M, Beneit P, Fernández Moreno A, Arnan Sangerman M..., **Bergua J**, et al. Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A “Real-Life” Multicenter Study. En: Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting; 25-27 de agosto de 2022; Los Angeles: 2022.

Labrador J, Martínez-Cuadron D, Boluda B..., **Bergua J**. Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study). En: 64th ASH Annual Meeting; 2022.

Sargas C, Ayala R, Larrayoz MJ..., **Bergua J**. Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications. En: 64th ASH Annual Meeting; 2022.

Simoes C, Villar S, Ariceta B..., **Bergua J**. Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML). En: 64th ASH Annual Meeting; 2022.

Suárez E, Alonso JM, Boluda B..., **Bergua J**. Prognostic Impact of *NPM1* and *FLT3*-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study. En: 64th ASH Annual Meeting; 2022.

Belada D, Kopeckova K, **Bergua Burgues JM**, Stevens D. **First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma**. En: 63RD ASH ANNUAL MEETING; 11-14 de diciembre de 2021; Atlanta: 2021.

Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F..., **Bergua JM**. **Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4**. En: 63RD ASH ANNUAL MEETING; 11-14 de diciembre de 2021; Atlanta: 2021.

Labrador J, Fuente A de la, Martínez-Cuadrón D, Rodríguez-Veiga R..., **Bergua Burgues JM**. **Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry**. En: 63RD ASH ANNUAL MEETING; 11-14 de diciembre de 2021; Atlanta: 2021.

Labrador J, Fuente A de la, Martínez-Cuadrón D, Rodríguez-Veiga R..., **Bergua Burgues JM**. **Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry**. En: 63RD ASH ANNUAL MEETING; 11-14 de diciembre de 2021; Atlanta: 2021.

Morschhauser F, Sehn LH, Friedberg JW, Trneny S ..., **Bergua Burgues JM**. **The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma**. En: 63RD ASH ANNUAL MEETING; 11-14 de diciembre de 2021; Atlanta: 2021.

Recher C, Rolling C, Berard E, Bertoli S..., **Bergua JM**. **Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries**

. En: 63RD ASH ANNUAL MEETING; 11-14 de diciembre de 2021; Atlanta: 2021.

Sargas C, Ayala R, Cillon C, Larrayoz MJ..., **Bergua JM**. [Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group](#) . En: 63RD ASH ANNUAL MEETING; 11-14 de diciembre de 2021; Atlanta: 2021.

Simoes CP, Chillon C, Martínez -Cuadrón D, Calasanz JM..., **Bergua Burgues JM**. [Integrated Multidimensional Flow Cytometry \(MFC\) and Next-Generation Sequencing \(NGS\) to Reconstruct Evolutionary Patterns from Dysplasia to Acute Myeloid Leukemia \(AML\)](#) . En: 63RD ASH ANNUAL MEETING; 11-14 de diciembre de 2021; Atlanta: 2021.

Labrador J, Martínez Cuadrón D, Fuente A de la, Rodríguez Veiga R, Serrano J, Tormo M, et al. [Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry](#) . En: 62nd ASH Annual Meeting ; 2020; Virtual: 2020.

Martínez López J, Montesinos P, Martínez Sánchez P, Gorrochategui J, Rojas JL, Prino D, et al. [Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates](#) . En: 62nd ASH Annual Meeting ; 2020; Virtual: 2020.

Martínez P, Palanques Pastor T, López Lorenzo JL, Cornago Navascués J, Rodríguez Macías G, Cano I, et al. [Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry](#) . En: 62nd ASH Annual Meeting ; 2020; Virtual: 2020.

Moriano B, **Bermejo N**, Rodríguez A, Espina M, Espina M, Ramos L, et al. [Antithrombotic treatment in patients with factor VII deficiency: case reports](#) . En: 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020; 5-7 de febrero de 2020; 2020.

Simoes CP, Paiva B, Martínez Cuadron D, **Bergua JM**, Vives S, Algarra JL, et al. [Measurable Residual Disease \(MRD\) in Elderly Acute Myeloid Leukemia \(AML\): Results from the Pethema-Flugaza Phase III Clinical Trial](#)

. En: 62nd ASH Annual Meeting ; 2020; Virtual: 2020.

Ayal RM, Rapado I, Martínez-Cuadron D, Onecha E, Rufian L, Juarez A, et al. [Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine \(FLUGA\) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial](#) . En: 61st ASH Annual Meeting; 7-10 de diciembre de 2019; Orlando, FL: 2019.

Bergua Burgues JM, Cano-Ferri I, Martínez Cuadron D, Boluda B, Martínez Sánchez P, Rodríguez Veiga R, et al. [Outcomes after Plerixafor Plus FLAG-IDA \(PLERIFLAG\) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry](#) . En: 61st ASH Annual Meeting; 7-10 de diciembre de 2019; Orlando, FL: 2019.

Cáceres Hernández S, Bañas Llanos H, Arcos Carmona MJ, Cardesa Cabrera R, Suárez Varela S, Casas Avilés I, et al. [Coexistence of lymphoplasmacytic lymphoma, multiple myeloma and myelodysplastic syndrome](#). En: XVI Congress of the Iberian Society of Cytometry; 9-11 de mayo de 2019; Salamanca: 2019.

Chiappella A, Witzig E, Cocks K, Greenwood M, Williams A, Scott DW, et al. [Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy \(R2-CHOP\) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell \(ABC\)-Type Diffuse Large B-Cell Lymphoma \(DLBCL\): Health-Related Quality of Life \(HRQoL\) Analysis of the International Robust Study](#). En: 61st ASH Annual Meeting; 7-10 de diciembre de 2019; Orlando, FL: 2019.

Moriano Palacios B, Ibáñez Espacio F, Cáceres Hernández S, Rodríguez López A, Arcos Carmona MJ, Suárez Varela Pineda S, et al. [Relación entre transfusión materna previa y enfermedad hemolítica del recién nacido mediada por anti-c y autoanticuerpo anti-d](#). En: 30 Congreso de la Sociedad Española de Transfusión Sanguínea y Terapia Celular; 6-8 de junio de 2019; Madrid: 2019.

Moriano Palacios BJ, Ferre Bermejo O, Cardesa Cabrera R, Suárez-Varela Pineda S, Cáceres Hernández S, Rodríguez López A, et al. [LMA NPM1 tras TE JAK2V617F: ¿transformación leucémica u origen de novo?](#) .

En: XVI Reunión Anual de la Sociedad Extremeña de Hematología y Hemoterapia; 15-16 de marzo de 2019; Plasencia: 2019.

Ribera JM, García Calduch O, Gil C, González Campos J, Moreno MJ, Barba P, et al. **Clinicobiologic characteristics and outcome of elderly frail patients with acute lymphoblastic leukemia included in a specific protocol (all-07FRAIL)**. En: 13-16 de junio de 2019; Amsterdam: 2019.

Ribera JM, García O, Cervera M, Rguez C, Sirvent M, Vall-Llovera F, et al. **Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients**. En: 61st ASH Annual Meeting; 7-10 de diciembre de 2019; Orlando, FL: 2019.

Ribera JM, Morgades M, Prob M, Ciudad J, Montesinos P, Barba P, et al. **Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial**. En: 61st ASH Annual Meeting; 7-10 de diciembre de 2019; Orlando, FL: 2019.

Vitolo U, Witzig TE, Gascoyne RD, Scott DW, Zhang QZ, Jurczak W, et al. **ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma**. En: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 18-22 de junio de 2019; Lugano, Switzerland: 2019.

Ballesteros J, Martínez Cuadrón D, Martínez López J, **Bergua Burgués J**, Trmo M, Serrano J, et al. **Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments**. En: 60th ASH Annual Meeting and Exposition; 1-4 de diciembre de 2018; San Diego, California: 2018.

Bergua J, Martínez Cuadrón D, Boluda B, Martínez P, Rodríguez Veiga R, Esteve J, et al. **Analysis of three salvage treatment regimens after relapsed/refractory acute myeloid leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG)**

. En: The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation; 18-21 de marzo de 2018; Lisboa: 2018.

Genesca E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, et al. **Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols** . En: 60th ASH Annual Meeting and Exposition; 1-4 de diciembre de 2018; San Diego, California: 2018.

González Barca E, Martín A, Bello JL, **Bergua Burgués J**, Panizo C, Encuentra M, et al. **Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group** . En: 60th ASH Annual Meeting and Exposition; 1-4 de diciembre de 2018; San Diego, California: 2018.

Martínez Cuadrón D, Ballesteros J, Martínez López J, Hernández P, Primo D, Gorrochategui J, et al. **A subset of AML patients shows different quimiosensitivity ex vivo profiles to anthracyclines and its combination with cytarabine; could precision medicine be the key selection criterion?** . En: 23rd Congress of the European Hematology Association; 14-17 de junio de 2018; Stockholm (Sweden): 2018.

Moriano Palacios B, **Cardesa Cabrera R**, Suárez Varela Pineda S, &10, **Pérez Leal F**, **Cáceres Hernández S**, et al. **Linfoma primario del sistema nervioso central y carcinoma de células renales concurrente: un caso inusual**. En: LX Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia; 11-13 de octubre de 2018; Granada: 2018.

Paiva B, Martínez Cuadrón D, **Bergua Burgués J**, Vives S, Lorenzo Algarra J, Tormo M, et al. **Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial** . En: 60th ASH Annual Meeting and Exposition; 1-4 de diciembre de 2018; San Diego, California: 2018.

Ribera Santasusana JM, Morgades de la Fe M, Montesinos Fernández P, Martínez Carballeira D, Tormo Díaz M, Gil Cortés C, et al. **Resultados finales del protocolo LAL-RI08 para adolescentes y adultos jóvenes (AAJ) con leucemia aguda linfoblástica (LAL) de riesgo estándar (RE)**

. En: LX Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia; 11-13 de octubre de 2018; Granada: 2018.

Zeidner J, Lin T, Vigil C, Dalovisio A, Wang E, Yair Levy M, et al. **Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)**. En: 60th ASH Annual Meeting and Exposition; 1-4 de diciembre de 2018; San Diego, California: 2018.

Baile M, Rodríguez G, Dlouhy I, Sancho JM, Jarque I, González Barca E, et al. **Lenalidomida en combinación con R-ESHAP en pacientes con linfoma difuso de células B grandes (LDCBG) refractorio o en recaída: estudio fase 2 del Grupo Español Geltamo** . En: LIX Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia; 26-28 de octubre de 2017; Málaga: 2017.

Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, et al. **Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials**. En: 59th ASH Annual Meeting; 9-12 de diciembre de 2017; Washington: 2017.

Deveaux M, Stahl M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. **Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)** . En: 59th ASH Annual Meeting; 9-12 de diciembre de 2017; Washington: 2017.

Gironella M, Alegre A, Escalante F, **Bergua JM**, Martínez Chamorro C, López A, et al. **Características diferenciales de los pacientes con mieloma múltiple (MM) que inician tratamiento de rescate tras una recaída clínica o biológica (EPA-MMBR)**. En: LIX Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia; 26-28 de octubre de 2017; Málaga: 2017.

Primo D, Hernández P, Serna J de la, Ribera JM, Vives S, **Bergua J**, et al. **Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy**

. En: 59th ASH Annual Meeting; 9-12 de diciembre de 2017; Washington: 2017.

Primo D, Martínez Cuadrón D, Montesinos P, De la Serna J, Ribera JM, Vives S, et al. **Nuevo modelo para cuantificar la actividad farmacológica in vitro de anticuerpos biespecíficos en hemopatías malignas** . En: LIX Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia; 26-28 de octubre de 2017; Málaga: 2017.

Ribera JM, Morgades M, Montesinos P, Martínez-Carballeira D, Gil C, Barba P, et al. **Results of the Full Pediatric, Minimal Residual Disease (MRD)-Oriented Trial LAL-RI/2008 for Adolescents and Young Adults (AYA) with Standard Risk (SR), Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL)** . En: 59th ASH Annual Meeting; 9-12 de diciembre de 2017; Atlanta: 2017.

Stahl M, Deveaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. **Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)— Transplant Outcomes Post HMA Therapy in a Large International Patient Cohort** . En: 59th ASH Annual Meeting; 9-12 de diciembre de 2017; Washington: 2017.

Bergua Burgues JM, López-Gómez L, Ibañez F, Suarez-Varela S, Prieto-Fernández J, Carnicero F, et al. **NCCN-IPI in Patients with Diffuse Large B CELL Lymphoma Treated with DA-R-EPOCH. Retrospective Analysis**. En: 58th ASH Annual Meeting [Publicado en Blood 2016 128(22); 3-6 diciembre 2016; San Diego: 2016.

Bermejo N, Sigüenza R, Casas I, Pérez-Leal FDA, Banas MH, Ibañez F, et al. **Anticoagulant treatment with apixaban in inherited antithrombin deficiency**. En: 21st Congress of the European Hematology Association; 9-12 de junio de 2016; Copenhagen: 2016.

Fernández Delarrea C, Escalante F, Alegre A, **Bergua JM**, Martínez Chamorro C, López A, et al. Do multiple myeloma R/R patients benefit from early treatment at biological relapse? preliminary results of a spanish observational prospective registry. En: 9-12 junio 2016; Copenhagen: 2016.

Montesinos P, Ballesteros J, Martínez Cuadron D, Martínez Lopez J, Serrano J, Pérez de Oteyza J, et al. An ex vivo native environment precision medicine test shows high clinical correlation with responses to first line acute myeloid leukemia treatment. En: 9-12 junio 2016; Copenhagen: 2016.

Montesinos P, Vives S, Martínez-Sánchez MP, **Bergua J**, Algarra L, Herrera P, et al. Preliminary Results of the Flugaza Trial: A Phase III Randomized, Open Label Study Comparing Azacytidine Versus Fludarabine and Cytarabine (FLUGA Scheme) in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia . En: 58th ASH Annual Meeting; 3-6 diciembre 2016 ; San Diego: 2016.

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, et al. Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalities (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group. En: 58th ASH Annual Meeting [Publicado en Blood 2016 128(22); 3-6 diciembre 2016; San Diego: 2016.

Ribera JM, García O, Gil C, Montesinos P, Martino R, González Campos J, et al. Intensive Vs semi-intensive chemotherapy in older adults (55-65 yr) with Philadelphia chromosome-negative acute lymphoblastic leukemia. En: [Publicado en Haematologica 2016 101(s1)]; 9-12 de junio de 2016; Copenhagen: 2016.

Ribera JM, Morgades M, Ciudad J, Montesinos P, Tormo M, González Campos J, et al. Lack of prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative, b-cell precursor all treated according to MRD oriented protocols. En: 9-12 junio 2016; Copenhagen: 2016.

Ribera JM, Morgades M, Montesinos P, García-Cadenas I, Barba P, Soria B, et al. Comparison of Efficacy and Safety of Two Types of E.coli Asparaginase (Native or Pegylated) for Treatment of Adult Patients with High-Risk (HR), Philadelphia (Ph) Chromosome-Negative ALL Included in the Prospective MRD-Oriented Protocol ALL-HR-11 from the. En: 58th ASH Annual Meeting [Publicado en Blood 2016 128(22); 3-6 de diciembre de 2016; San Diego: 2016.

Sigüenza R, Bermejo N, Casas I, Pérez FD, Fernández H, Ibañez F, et al. Relationship between type and intensity of anticoagulant therapy and recurrence of arterial thrombosis on antiphospholipid syndrome . En: [Publicado en Haematologica 2016 101(s1)]; 9-12 de junio de 2016; Copenhagen: 2016.

Vives S, Martínez-Sánchez MD, Bergua J, Algarra L, Herrera Pilar MD, Tormo M, et al. Preliminary results of the flugaza trial: a phase iii randomized, open label study comparing azacytidine versus fludarabine and cytarabine (fluga scheme) in elderly patients with newly diagnosed acute myeloid leukemia . En: 58th ASH Annual Meeting; 3-6 de diciembre; San Diego: 2016.

Bermejo N, Sigüenza R, Ibañez F, Bañas MH, Casas I, Pérez-Leal FA, et al. Long-term anticoagulation with dabigatran in patients with severe lactose intolerance . En: 20th Congress of the European Hematology Association; 11-14 junio 2015; Viena., Austria: 2015.

Falantes JF, Martínez Robles V, Bargay J, Deben G, Garrido A, Casano J, et al. Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score. En: ASCO Annual Meeting; 29 de mayo- 2 de junio de 2015; Chicago: 2015.

Gironella M, Bergua J, Fernández de Larrea C, Escalante F, González M, Martínez Chamorro C, et al. Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry . En: ASH Meeting 2015; dic.-15; Orlando: 2015.

Montesinos P, Ballesteros J, Martínez Cuadrón D, Martínez López J, Serrano J, Pérez de Oteyza J, et al. High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test. En: ASH Meeting 2015; dic.-15; Orlando: 2015 .

Pineda A, Sancho JM, García O, Esteve J, Tormo M, Martínez P, et al. Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain. En: ASH Meeting 2015; diciembre de 2015; Orlando: 2015.

Ribera JM, Morgades M, Ciudad J, Barba P, Martino R, Montesinos P, et al. Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). P. En: ASH Meeting 2015; diciembre de 2015; Orlando: 2015 .

Sigüenza R, Bañas MH, Casas I, Ibañez F, Bermejo N, Bergua JM, et al. CD38 expression on CD34+ Bone Marrow Cells (BM) as a tool in low grade Myelodysplastics Syndromes (MDS) . En: 20th Congress of the European Hematology Association.; 11-14 junio 2015; Vienna, Austria: 2015.

Sigüenza R, Bermejo N, Casas I, Ibañez F, Bañas MH, Bergua JM, et al. [Relationship between Antiphospholipid Syndrome clinical manifestations and multiple positive antiphospholipid antibodies.](#) . En: 20th Congress of the European Hematology Association; 11-14 de junio de 2015; Vienna, Austria: 2015.

Alegre A, Gironella M, Bergua JM, González E, Esacalante F, Soler A, et al. [Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse.](#) . En: 56th ASH Annual Meeting and Exposition. Publicado en Blood 2014 124(21) (Espec Congr): 4765; 6-9 de diciembre de 2014; San Francisco: 2014.

Bergua Burgues JM, Sigüenza R, Pazos C, Fernandez-Leyva H, Ibañez F, Prieto J, et al. [Relevance of parallel use of galactomanann and betaglucan assay in the diagnosis and follow up of fungal infection.](#) . En: 19th Congress of the European Hematology Association; 12-15 de junio de 2014; Milan: 2014.

Bergua JM, Montesinos P, Martínez-Cuadrón D, Fernández-Abellán P, Serrano J, Sayas MJ, et al. [A prognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-Ida or Flago-Ida.](#) . En: ASH Meeting 2014. Publicado en Blood 2014 124(21) (Espec Congr): 1049; dic.-14; 2014.

Bermejo N, Martín Aguilera C, Bañas H, Arcos MJ, Ibañez F, Salgado R, et al. [How we should treat the patients with cryptogenic ischemic stroke or transient ischemic attacks and antiphospholipid syndrome?](#) . En: 19th Congress of the European Hematology Association; 12-15 de junio de 2014; Milan: 2014.

De La Fuente A, Deben G, Bargay J, Garrido A, Serrano A, Salamero O, et al. [Acute myeloid leukemia in patients 70 and above. Azacitidine versus intensive chemotherapy.](#) . En: 19th Congress of the European Hematology Association; 12-15 de junio de 2014; Milan: 2014.

Falantes J, Deben G, Martínez Robles V, Bargay J, Salamero O, Pedro C, et al. **Azacitidine in older patients with acute Myeloid leukemia (AML) and adverse karyotype. Subanalysis from the Alma Study** . En: ASH Meeting 2014. Publicado en Blood 2014 124(21) (Espec Congr): 5311; diciembre 2014; 2014.

Falantes J.F, Debén G, Martínez-Robles V, Bargay J, Salamero O, Pedro C, et al. **Papel de azacitidina en pacientes con leucemia aguda mieloblástica con cariotipo adverso. Subanálisis del estudio ALMA** . En: Sociedad Española de Hematología y Hemoterapia Sociedad Española de Trombosis y Hemostasia - 52 Reunión Nacional SEHH, 26 Congreso Nacional de la SETH; 6-8 de noviembre de 2014; Madrid: 2014.

Hernández P, Montesinos P, Serrano J, Herrera P, **Bergua J**, Colorado M, et al. **Novel assay for ex vivo evaluation of antiproliferative effect of hypomethylating agents 5-Azacitidine and Decitabine in AML patient samples**. En: ASH Meeting 2014. Publicado en Blood 2014 124(21) (Espec Congr): 5311; diciembre 2014; 2014.

Martínez-López J, Montesinos P, González M, Barragán E, Ayala R, Martínez Laperche C, et al. **Impacto de las mutaciones FLT3-ITD en la respuesta al tratamiento con quimioterapia intensiva en pacientes jóvenes con leucemia mieloide aguda** . En: Sociedad Española de Hematología y Hemoterapia Sociedad Española de Trombosis y Hemostasia - 52 Reunión Nacional SEHH, 26 Congreso Nacional de la SETH; 6-8 de noviembre de 2014; Madrid: 2014.

Rodríguez Veiga R, Montesinos Fernández P, Holowiecka A, Vellenga E, Rayón C, Rivas C, et al. **Incidencia y factores de riesgo para desarrollo de eventos tromboembólicos en 921 pacientes con leucemia promielocítica aguda registrados en los protocolos pethema LPA2005 Y LPA2012** . En: Sociedad Española de Hematología y Hemoterapia Sociedad Española de Trombosis y Hemostasia - 52 Reunión Nacional SEHH, 26 Congreso Nacional de la SETH; 6-8 de noviembre de 2014; Madrid: 2014.

Sigüenza Salgado R, Ibáñez Espacio F, Casas Avilés I, Flores Guerrero A, Bañas Llanos H, Martín Aguilera C, et al. **Dos pacientes mujeres, jóvenes, con fiebre y un mismo destino**. En: X Jornadas Transfronterizas de Medicina Interna; 9-10 de mayo de 2014; Elvas: 2014.

Bañas Llanos MH, Ibañez Espacio F, Martín-Aguilera C, Arcos Carmona MJ, Carnicero F, Cabrera C, et al. **Flow cytometric CD38 expression on CD34+ cells as a simple diagnostic test in myelodysplastic syndromes (MDS)**. En: 12th International Symposium on Myelodysplastic Syndromes; 8-11 de mayo de 2013; Berlin: 2013. p. 55-56

Barba P, Oriol A, Grande C, Abrisqueta P, González Campos MD, Tormo M, et al. **Intensive Immunochemotherapy In Patients With B-Cell Lymphoma, Unclassifiable (B-UCL), With Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Burkitt Lymphoma (BL): A Comparison With BL Patients Treated With The Same Protocol In The**. En: 55th ASH Annual Meeting And Exposition; 7-10 de diciembre de 2013; New Orleans: 2013.

Bergua Burgués J, Arcos MJ, Carnicero F, Prieto J, Cabrera C, Martín-Mateos ML, et al. **Azacytidine 75 mg/m² x5 day in high-risk myelodysplastic syndromes and acute myeloid leukemia refractory/relapsed patients**. En: 12th International Symposium on Myelodysplastic Syndromes; 2013. p. 155-155

Bergua Burgués J, Montesinos P, Martínez Cuadrón D, Serrano J, Fernández P, Rayón C, et al. **Treatment with FLAG-IDA or FLAGO-IDA regimen in adult patients with relapsed/refractory acute myeloid leukemia. Retrospective analysis of the PETHEMA AML Registry**. En: 18th Congress of the European Hematology Association; 13-16 de junio de 2013; Stockholm, Sweden: 2013.

Fuente A de la, Deben G, Bargay J, Garrido A, Serrano J, Salamero O, et al. **Leucemia mieloide aguda en pacientes menores de 70 años. Poliquimioterapia vs. azacitidina en primera línea**. En: XXIX Congreso

Nacional de la Sociedad Española de Trombosis y Hemostasia (SETH); 17-19 de octubre de 2013; Sevilla: 2013.

Haya S, Martín M, Parra R, Soto I, López MF, Moreno M, et al. [Registro español de inmunotolerancia en hemofílicos con inhibidores. Actualización a 2012](#). En: XXIX Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia (SETH). Comunicaciones orales; 17-19 de octubre de 2013; Sevilla: 2013.

Ibañez F, Fernández H, Bermejo N, Arcos MJ, Martín C, Carnicero F, et al. [Antyphospholipid syndrome and arterial thrombosis \[EPosters\]](#). En: XXIV Congress of the international society on thrombosis and haemostasis. 59th Annual SSC Meeting; 29 junio-4 de julio de 2013; Amsterdam: 2013.

Martínez-Cuadrón D, Lassaletta A, Montesinos P, Verdeguer A, De la Serna J, Bastida P, et al. [Characteristics and therapeutic results in APL pediatric patients: analysis of the PETHEMA trials](#) . En: 6th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA; 29 septiembre-2 de octubre de 2013; Roma: 2013.

Montesinos P, Martínez-Cuadrón D, Lavilla E, Díaz-Mediavilla J, Herrera P, García R, et al. [Intensive \(2+5\) Or Semi-Intensive \(FLUGA\) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older](#). En: ASH Annual Meeting; 7 - 10 de diciembre de 2013; New Orleans: 2013.

Montesinos P, Martínez-Cuadrón D, Lavilla E, Díaz-Mediavilla J, Herrera P, García Raimundo, et al. [Intensive \(2+5\) Or Semi-Intensive \(FLUGA\) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older](#). En: 55th ASH Annual Meeting And Exposition; 7-10 de diciembre de 2013; New Orleans: 2013.

MontesinosR, Martínez Cuadrón D, Fernández P, García R, Serrano A, Bergua J, et al. Tratamiento con quimioterapia intensiva (2 + 5) o semiintensiva (FLUGA) en pacientes de 65 a 69 años con leucemia mieloblástica aguda. En: XXIX Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia (SETH); 17-19 de octubre de 2013; Sevilla: 2013.

MontesinosR, Martínez Cuadrón D, Lavilla E, Díaz Mediavilla J, Herrera P, García R, et al. Tratamiento con quimioterapia intensiva (2 + 5) o semiintensiva (FLUGA) en pacientes de edad mayor o igual a 70 años con leucemia mieloblástica aguda. En: XXIX Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia (SETH). Pósters; 17-19 de octubre de 2013; Sevilla: 2013.

Rodríguez-Veiga R, Montesinos P, Holowiecka A, Vellenga E, Rayón C, Rivas C, et al. Incidence and risk factors for thrombosis in 921 patients with acute promyelocytic leukemia registered in the PETHEMA LPA2005 & LPA2012 trials. En: 6th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA; 29 septiembre-2 de octubre de 2013; Roma: 2013.

Fernández H, Bermejo Vega N, Martín Aguilera C, Carnicero F, Ibañez Espacio F, Arcos Carmona MJ, et al. Understanding recurrent thrombosis of antiphospholipid syndrome. . En: 22nd International Congress on Thrombosis; 6-9 de octubre de 2012; Nice, Francia: 2012. p. S163

Ramos F, Martínez-Robles V, Bargay J, Deben G, Garrido A, Serrano J, et al. Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators . En: 54 ASH Annual Meeting; 8-11 de diciembre de 2012; Atlanta: 2012.

Bergua J, Arcos Carmona MJ, Prieto Fernández J, Cabrera Silva C, Carnicero F, Fernández Leyva H, et al. Azacytidine 75mg/m²x5 day in high risk myelodysplastic syndromes and acute myeloid leukemia refractory relapses patients: results from a single centre. En: 11th International Symposium on Myelodysplastic

Syndromes; 18-21 de mayo de 2011; Edimburg: 2011. p. s63

Bermejo N, Martín C, Bengochea ML, Bañas H, Fernández Leyva H, Ferrando L, et al. **Recurrencia trombótica en síndrome antifosfolípido**. En: LIII Reunión Nacional de la SEHH y XXVII Congreso Nacional de la SETH; 27-29 de octubre de 2011; Zaragoza: 2011.

Fernández Leyva H, Ferrando L, Ibáñez F, Martín C, Arcos MJ, Prieto J, et al. **La clasificación de Hans en pacientes afectos de linfoma no Hodgkin B de alto grado no sirve cuando se utiliza el protocolo R-EPOCH** . En: LIII Reunión Nacional de la SEHH y XXVII Congreso Nacional de la SETH; 27-29 de octubre de 2011; Zaragoza: 2011.

Fuente A de la, Debén G, . Bethencourt C, Negri S, Vilariño D, González S, et al. **Experiencia española del uso compasivo de clofarabina en el tratamiento de la leucemia mieloide aguda** . En: LIII Reunión Nacional de la SEHH y XXVII Congreso Nacional de la SETH; 27-29 de octubre de 2011; Zaragoza: 2011.

Izquierdo F, Fernández-Leyva H, Prieto-Fernández J, Bengochea-Miranda M, Carnicero F, Cabrera C, et al. **Encefalopatía reversible posterior en pacientes afectos de leucemia aguda linfoblástica** . En: LIII RunióN Nacional de la SEHH y XXVII Congreso Nacional de la SETH; 27-29 de octubre de 2011; Zaragoza: 2011.

Prieto Fernández J, Fernández Leyva H, Bengochea Miranda M, Carnicecero F, Cabrera C, Martín Mateos ML, et al. **Trasplante autólogo en pacientes afectos de leucemia aguda mieloblástica. Resultados de una serie de 22 pacientes**. En: LIII RunióN Nacional de la SEHH y XXVII Congreso Nacional de la SETH; 27-29 de octubre de 2011; Zaragoza: 2011.

Purroy N, Bergua J, Gallur L, Prieto J, Sancho JM, López L, et al. **Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group** . En: 53rd American Society of Hematology Annual Meeting and Exposition; 10-13 de diciembre de 2011; Atlanta, Georgia: 2011.

Ribera JM, García O, Grande C, Esteve J, **Bergua J**, Oriol A, et al. **Quimioterapia específica y rituximab en pacientes con linfoma/leucemia de Burkitt, independientemente de la infección por el VIH. Resultados de un estudio en fase II (Burkimab)**. En: LIII Reunión Nacional de la SEHH y XXVII Congreso Nacional de la SETH; 27-29 de octubre de 2011; Zaragoza: 2011.

Sánchez Correa B, Gayoso I, **Arcos MJ**, Bengochea ML, Casado JG, Morgado S, et al. **Análisis fenotípico de poblaciones NK al diagnóstico en pacientes con leucemia aguda mieloblástica. Correlación clínica**. En: LIII Reunión Nacional de la SEHH y XXVII Congreso Nacional de la SETH; 27-29 de octubre de 2011; Zaragoza: 2011.

Cruz Vicente F, Rubio V, Gil Esparraga E, **Bergua J**, González E. **Influenza A (H1N1) virus infection in hematologic patients in the south and west of Spain**. En: 52nd ASH Annual Meeting and Exposition; 4-7 de diciembre de 2010; Orlando: 2010.

Herránz M, López Lafuente A, Barros García P, Surribas Murillo C, **González García MJ**, **Bergua J**, et al. **Trombocitopenia Autoinmune y Anemia Hemolítica: Descripción de un caso en lactante de 3 meses (Abstract)**. En: XCII Reunión Científica de la Sociedad de Pediatría de Andalucía Occidental y Extremadura; 10 de noviembre de 2006; 2006.

Capote FJ, E. González-Barca, **JM Bergua**, M.J. Pascual, R. García-Boyero, J.M. Ribera, et al. **Autologous stem cell transplantation and rituximab for mantle cell lymphoma**. En: American Society of Hematology Forty-seventh Annual Meeting; 10-13 de diciembre de 2005; Atlanta, Georgia: 2005.

Bermejo Vega N, Ibáñez Espacio F, Carnicero F, Sigüenza Salgado R, Casas Avilés I, Pérez Leal FA, et al. [Anticoagulantes orales directos en síndrome antifosfolípido: una serie de casos](#) . En: XXXII Congreso Nacional de la SETH; 20-22 octubre 2016; Santiago de Compostela: 2016.

Martín A, Baile M, Rodríguez G, Dlouhy I, Sancho JM, Jarque I, et al. [Lenalidomide in Combination with R-ESHAP \(LR-ESHAP\) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Candidates for Autologous Stem-Cell Transplantation: A Phase 2 Study from the Spanish Group Geltamo](#) . En: 58th ASH Annual Meeting [Publicado en Blood 2016 128(22); 3-6 diciembre 2016; San Diego: 2016.

Ribera Santasusana Jose Maria, García Olga, Gil Cristina, Montesinos Pau, Martino Rodrigo, González Campos José, et al. [Quimioterapia intensiva frente a semi-intensiva en pacientes adultos de edad avanzada \(55-65años\) con leucemia aguda linfoblástica \(LAL\) sin cromosoma filadelfia \(PH-NEG\)](#) . En: XXXII Congreso Nacional de la SETH [Publicado en Haematologica 2016 101(s1)]; 20-22 de octubre de 2016; Santiago de Compostela: 2016.

Trabajos presentados a Congresos y publicados en formato electrónico

Belada D, Nowakowski GS, Bergua Burgués JM, André M, Kopeckova K, Stevens DA, et al. [A phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab \(MOR208\) or Tafasitamab+ Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B cell –lymphoma: Analysis of the Safety Run in Phase](#) . [Internet]. 2020: (63rd ASH Annual Meeting and Exposition) 5 de noviembre de 2020. Virtual congress [Consultado el 11 de mayo de 2021].

Espina García M, Ibáñez Espacio F, Cáceres Hernández S, Arcos Carmona MJ, Casas Avilés I, Ferre Bermejo O, et al. [Eritrocitosis inexplicada](#) . [Internet]. 2020: (LXII Congreso Nacional de la SEHH. XXXVI

Congreso Nacional de la SETH Virtual) 26-30 de octubre de 2020. [Consultado el 14 de junio de 2021].

González Barca E, Martín A, Bello JL, **Bergua JM**, Panizo C, Encuentra M, et al. [Comparación entre cinco índices pronósticos en una serie de 87 pacientes con linfoma T/NK tipo nasal](#) . [Internet]. 2020: (LXII Congreso Nacional de la SEHH. XXXVI Congreso Nacional de la SETH Virtual) 26-30 de octubre de 2020. [Consultado el 14 de junio de 2021].

Martín A, Chavez J, Abrisqueta P, Johnson NA, **Bergua Burgués JM**, Grande-García C, et al. [Phase I/II study of avadomide \(CC-122\) in combination with R-CHOP for newly diagnosed DLBCL](#) . [Internet]. 2020: (EHA25 Virtual) 11-21 de junio de 2020. Virtual congress [Consultado el 11 de mayo de 2021].

Martínez-Cuadrón D, Serrano J, Martínez O, Pérez-Simón JA, Gil C ..., **Bergua JM**, et al. [Characteristics and treatment strategies of Secondary Acute Myeloid Leukemia Patients: Data from the PETHEMA AML epidemiological registry](#) . [Internet]. 2020: (EHA25 Virtual) 11-21 de junio de 2020. Virtual congress [Consultado el 11 de mayo de 2021].

Mehta-Shah N, Chavez JC, Abrisqueta P, Johnson N, **Bergua Burgues JM**, Grande-García C, et al. [Phase I/II study of avadomide \(CC-122\) in combination with R-CHOP for newly diagnosed DLBCL](#) . [Internet]. 2020: (ASCO Annual Meeting 2020) . [Consultado el 10 de mayo de 2021].

Primo D, Pérez Oteyza J, **Bergua JM**, Hernández Rivas JA, Ruiz E, Vives S, et al. [Bispecific T cell engager antibodies may contribute to reactivate pre-existing tumor specific T cells](#) . [Internet]. 2020: (EHA25 Virtual) 11-21 de junio de 2020. Virtual congress [Consultado el 11 de mayo de 2021].

Sargas Simarro C, Ayala Díaz R, Chillón Santos C, Larráyoiz Ilundáin MJ, Carrillo Cruz E..., **Bergua Burgues J**, et al. [Red nacional para el diagnóstico molecular avanzado en leucemia mieloide aguda: proyecto PETHEMA NGS-LMA](#) . [Internet]. 2020: (LXII Congreso Nacional de la SEHH. XXXVI Congreso Nacional de la SETH Virtual) 26-30 de octubre de 2020. [Consultado el 14 de junio de 2021].

Simoës C, Paiva B, Martínez-Cuadrón D, **Bergua JM**, Vives S, Algarra L, et al. **Enfermedad mínima residual en pacientes con leucemia mieloblástica aguda(LMA) de edad avanzada: resultados del ensayo clínico fase III PETHEMA FLUGAZA**. [Internet]. 2020: (LXII Congreso Nacional de la SEHH. XXXVI Congreso Nacional de la SETH Virtual) 26-30 de octubre de 2020. [Consultado el 14 de junio de 2021].

Tormo M, Díaz Beya M, Berneit P, Fernández A, Arnant M..., **Bergua JM**, et al. **Midostaurin in combination with intensive chemotherapy in patients iwth FLT3-mutated acute myeloid leukemia (AML). A real life multicenter experience from Spanish Tertiary Hospitals**. [Internet]. 2020: (EHA25 Virtual) 11-21 de junio de 2020. Virtual congress [Consultado el 11 de mayo de 2021].

Zabaleta A, Alameda D, Ajona C, Perez C, Alignani D, ..., et al. **The mode of action (MOA) of the anti-CD38 monoclonal antibody (MAB) Isatuximab in elderly acute myeloid leukemia**. [Internet]. 2020: (EHA25 Virtual) 11-21 de junio de 2020. Virtual congress [Consultado el 11 de mayo de 2021].

Barba Pere, Morgades Mireia, Montesinos Pau, Gil Cristina, Fox María Laura, Ciudad Juana, et al. **Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials**. En: Blood 2017 130:1323. 2017: (59th ASH Annual Meeting) 9-12 diciembre . Atlanta, GA

Deveaux M, Stahl M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. **Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)**. [Internet]. 2017: (59th ASH Annual Meeting) 9-12 diciembre . Atlanta, GA Blood 2017 130:

Montesinos P, Ballesteros J, Martínez Cuadron D, Martínez López J, Errano J, Pérez de Oteyza J, et al. **Validation of precision medicine test for acute myeloid leukemia in an observational clinial trial**. En: Abstract

Book. 22nd Congress of the European Hematology Association. [Internet]. 2017: (22nd Congress of the European Hematology Association) 22-25 de junio de 2017. Madrid

Primo D, Hernández P, Ghia P, Serna J de la, Ribera JM, Vives S, et al. [A novel in vitro method to quantify the pharmacology activity of bispecific antibodies in hematological samples](#) . En: Abstract Book. 22nd Congress of the European Hematology Association. [Internet]. 2017: (22nd Congress of the European Hematology Association) 22-25 de junio de 2017. Madrid

Primo D, Hernández P, Serna J de la, Ribera JM, Vives S, **Bergua J**, et al. [Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy](#) . En: Blood 2017 130:2289. 2017: (59th ASH Annual Meeting) 9-12 diciembre . Atlanta, GA

Stahl M, Deveaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. [Hypomethylating Agents \(HMAs\) in Patients with Relapsed and Refractory Acute Myeloid Leukemia \(RR-AML\)— Transplant Outcomes Post HMA Therapy in a Large International Patient Cohort](#) . [Internet]. 2017: (59th ASH Annual Meeting) 9-12 de diciembre de 2017. Atlanta, GA

Stahl M, Deveaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. [The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis](#) . [Internet]. 2017: (59th ASH Annual Meeting) 9-12 de diciembre de 2017. Atlanta, GA [Consultado el 19 de enero de 2018].

Estudio de investigación

Zamorano J, Prieto J, **Bergua J**. [Caracterización de mediadores de muerte celular útiles para valorar la actividad antileucémica de interferones](#). Código de protocolo: BS10004 [2011-2013]. Fecha de aprobación: 2011,2012,2013.

Documentos docentes

Algarra L, Gil Cortés C, Balerdi A, Labrador J, **Bergua J**, García R, et al. Recomendaciones para el tratamiento de primera línea adaptado al riesgo de la LMA en pacientes candidatos a quimioterapia intensiva (no NPM1 no CBF no MPAL). [Protocolos] Hematología y Hemoterapia. 7 de enero de 2026.

Algarra L, Botella C, Vives S..., **Bergua J**. Recomendaciones PETHEMA 2025 para el tratamiento de la leucemia mieloblástica aguda en pacientes ancianos (70+) y/o no candidatos a quimioterapia intensiva (unfit). Guía asistencial Paciente Anciano Paciente Unfit (Guía PAPU-70+). Hematología y Hemoterapia. 01 de agosto de 2025.

Bergua J. Leucemia aguda promielocítica. [Sesión General] Hematología y Hemoterapia. 4 de octubre de 2012.